Kronox Lab Sciences Limited has informed the Exchange regarding 'Submission of Financial Results in Machine Readable Format for the BM held on 22nd May, 2025'.
KRONOX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kronox Lab Sciences reported FY25 revenue from operations of Rs. 10,019.39 lakhs, up 11.5% from Rs. 8,986.24 lakhs in FY24. Profit after tax grew to Rs. 2,546.71 lakhs vs Rs. 2,135.13 lakhs, a 19.3% rise, with EPS improving to Rs. 6.91 from Rs. 5.81. Q4 FY25 revenue rose to Rs. 2,613.11 lakhs (vs Rs. 2,217.64 lakhs in Q4 FY24) and Q4 PAT came in at Rs. 6,31.52 lakhs. Operating cash flow remained healthy at Rs. 3,069.66 lakhs (vs Rs. 1,741.51 lakhs). The statutory auditor (Mahesh Udhwani & Associates) issued an unmodified opinion, and the company operates in a single segment — high-purity specialty fine chemicals.
Solid double-digit revenue growth, ~20% PAT growth, and expanding margins signal improving business momentum for shareholders. A clean audit report with unmodified opinion removes any near-term concerns about earnings quality.